The anti-apoptotic gene survivin contributes to teratoma formation by human embryonic stem cells

Teratomas derived from human embryonic stem (hES) cells are unique among oncogenic phenomena as they are polyclonal and develop from apparently normal cells. A deeper understanding of this process should aid in the development of safer cell therapies and may help elucidate the basic principles of tumor initiation. We find that transplantation of diploid hES cells from four independent cell lines generates benign teratomas with no sign of malignancy or persisting embryonal carcinoma-like cells. In contrast, mouse embryonic stem (mES) cells from four cell lines consistently generate malignant teratocarcinomas. Global gene expression analysis shows that survivin (BIRC5), an anti-apoptotic oncofetal gene, is highly expressed in hES cells and teratomas but not in embryoid bodies. Genetic and pharmacological ablation of survivin induces apoptosis in hES cells and in teratomas both in vitro and in vivo. We suggest that continued expression of survivin upon differentiation in vivo may contribute to teratoma formation by hES cells.

[1]  R. Weinberg,et al.  Species- and cell type-specific requirements for cellular transformation. , 2004, Cancer cell.

[2]  D. Altieri.  Survivin, cancer networks and pathway-directed drug discovery , 2008, Nature Reviews Cancer.

[3]  P. Andrews,et al.  The terminology of teratocarcinomas and teratomas , 2007, Nature Biotechnology.

[4]  N. Benvenisty,et al.  Clonal Analysis of Human Embryonic Stem Cell Differentiation into Teratomas , 2007, Stem cells.

[5]  P. Andrews,et al.  Ultrastructural differentiation of a clonal human embryonal carcinoma cell line in vitro. , 1983, Cancer research.

[6]  Tamar Dvash,et al.  Temporal gene expression during differentiation of human embryonic stem cells and embryoid bodies. , 2004, Human reproduction.

[7]  M. Schuldiner,et al.  Establishment of human embryonic stem cell-transfected clones carrying a marker for undifferentiated cells , 2001, Current Biology.

[8]  J. Diebold,et al.  Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. , 1998, The American journal of pathology.

[9]  M. Schuldiner,et al.  Differentiation of Human Embryonic Stem Cells into Embryoid Bodies Comprising the Three Embryonic Germ Layers , 1999 .

[10]  H. Walt,et al.  Experimental testicular germ cell tumorigenesis in mouse strains with and without spontaneous tumours differs from development of germ cell tumours of the adult human testis. , 1993, International journal of andrology.

[11]  J. Thomson,et al.  Embryonic stem cell lines derived from human blastocysts. , 1998, Science.

[12]  David Botstein,et al.  SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data , 2003, Nucleic Acids Res..

[13]  D. Altieri,et al.  Inhibition of melanoma tumor growth in vivo by survivin targeting. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. Housman,et al.  Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Tward,et al.  Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC , 2007, Nature Medicine.

[16]  J. Li,et al.  Cancer gene therapy using a survivin mutant adenovirus. , 2001, The Journal of clinical investigation.

[17]  D. Altieri,et al.  A p34(cdc2) survival checkpoint in cancer. , 2002, Cancer cell.

[18]  N. Benvenisty,et al.  The tumorigenicity of human embryonic stem cells. , 2008, Advances in cancer research.

[19]  D. Vaux,et al.  Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype , 2000, Current Biology.

[20]  Yushu Ma,et al.  High-level expression, purification and pro-apoptosis activity of HIV-TAT-survivin (T34A) mutant to cancer cells in vitro. , 2006, Journal of biotechnology.

[21]  P. Andrews,et al.  Adaptation to culture of human embryonic stem cells and oncogenesis in vivo , 2007, Nature Biotechnology.

[22]  A. Hart,et al.  The pluripotency homeobox gene NANOG is expressed in human germ cell tumors , 2005, Cancer.

[23]  J. Thomson,et al.  Human ERas Gene Has an Upstream Premature Polyadenylation Signal That Results in a Truncated, Noncoding Transcript , 2005, Stem cells.

[24]  S. Yamanaka,et al.  Role of ERas in promoting tumour-like properties in mouse embryonic stem cells , 2003, Nature.

[25]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[26]  Fengzhi Li,et al.  Control of apoptosis and mitotic spindle checkpoint by survivin , 1998, Nature.

[27]  Monika Engelhardt,et al.  Telomerase activity in germ cell cancers and mature teratomas. , 1999, Journal of the National Cancer Institute.

[28]  M. Schuldiner,et al.  Selective Ablation of Human Embryonic Stem Cells Expressing a “Suicide” Gene , 2003, Stem cells.

[29]  J. Kononen,et al.  POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. , 2003, Cancer research.

[30]  Alana Welm,et al.  Cell division and cell survival in the absence of survivin. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Chad A. Cowan,et al.  Derivation of embryonic stem-cell lines from human blastocysts. , 2004, The New England journal of medicine.

[32]  M. Evans,et al.  The morphology and growth of a pluripotent teratocarcinoma cell line and its derivatives in tissue culture. , 1974, Cell.

[33]  Y. Bergman,et al.  Oct-3/4 is a dose-dependent oncogenic fate determinant. , 2003, Cancer cell.

[34]  벤자민 프라이어,et al.  Differentiation of human embryonic stem cells , 2011 .

[35]  T. Ince,et al.  The terminology of teratocarcinomas and teratomas , 2007, Nature Biotechnology.

[36]  L. Looijenga,et al.  Testicular germ-cell tumours in a broader perspective , 2005, Nature Reviews Cancer.